NEW YORK (GenomeWeb) – CRISPR Therapeutics announced today that it has raised an additional $38 million as part of a Series B Financing round.

The company said the funding round raised almost $140 million overall, with the first part of the financing being led by Vertex Pharmaceuticals and Bayer Global Investments, and the second, oversubscribed closing including new institutional investors and specialized healthcare funds such as Franklin Templeton Investments, New Leaf Venture Partners, and funds advised by Clough Capital Partners and Wellington Capital Management.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.